Preliminary results from the trial included patients with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer following surgery and chemotherapy, and demonstrated serum tumor biomarker reduction and notable immune responses in 80% of patients [54]. Here, KRAS is linked to neoplasm.